If left undiagnosed and untreated for a prolonged period, fatty liver disease can progress to more serious conditions, such as cirrhosis and liver cancer.
All over the United States, countless research projects designed to improve outcomes have lost funding or been shut down. Even screening efforts targeting patients in impoverished communities have been impacted by these policies.
The first 250 patients has been enrolled in the CORCINCH-HF U.S. pivotal trial evaluating the AccuCinch Transcatheter Left Ventricular Restoration System in patients with HFrEF.
Startup vendor FIRE1 completed patient enrollment in its U.S. early feasibility study for a heart failure remote monitoring device that directly measures fluid volume inside the IVC.
Cerebral protection devices, designed to limit the risk of stroke during transcatheter aortic valve replacement, may be especially helpful when patients undergo valve-in-valve TAVR.